Colitis with common immune checkpoint inhibitors: Incidence of diarrhea and colitis, and time to onset
| Immune check-point inhibitor | Diarrhea (%) | Colitis (%) | Time to onset of colitis |
|---|---|---|---|
| Ipilimumab | 25.7%–30% | 7.7%–11.6% | 6–7 weeks |
| Nivolumab | 11%–16% | 0.5%–1.1% | 6–18 weeks |
| Pembrolizumab | 1.2%–8% | 1%–2% | 6–18 weeks |
| Atezolizumab | 2% | 0.5% | 6–18 weeks |